Lyka Labs (LYKALABS)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding of 58.16% aligns management with minority shareholders.
• ROCE of 9.91% is positive and far above the negative ROE, indicating some operational asset efficiency.
• Book value of ₹37.13 provides a tangible asset base to assess downside.
• Latest quarter sales of ₹31 crore still represent meaningful revenue generation despite the annual decline.

Concerns

• Profit growth of -100% and P/E of 0.00 mean the company is currently earning nothing for shareholders.
• Sales declined 9.08%, showing shrinking business activity.
• ROE of -0.94% and Piotroski score of 3/9 signal poor profitability and weak financial health.
• Trading at ₹59.21, a 59% premium to book value of ₹37.13, offers no margin of safety.

AI Analysis

Lyka Labs is exactly the kind of stock that makes me pause. A pharmaceutical company selling at ₹59.21 with a market cap of ₹223 crore, yet it earns nothing. The P/E is meaningless at 0.00 because profits have disappeared. Over the latest quarter, sales were ₹31 crore and net profit was roughly zero. Over the year, sales fell 9.08% and profit growth collapsed by 100%. This is not a business with visible earning power; it is a business in distress or transition. The balance sheet shows a book value of ₹37.13, so at ₹59.21 I am paying 1.59 times book for a company that returns -0.94% on equity. That fails my test of buying decent businesses at fair prices. The Piotroski score of 3 out of 9 confirms weak financial health. On the positive side, return on capital employed is 9.91%, which is better than the negative ROE and suggests some underlying asset productivity. Promoter holding is high at 58.16%, which aligns interests, but ownership alone cannot justify a premium valuation. There is no dividend to compensate me while I wait. The 52-week range of ₹44.10 to ₹102.99 shows how volatile and speculative this stock has been. I would need a clear path to sustained profitability, evidence that sales decline has reversed, and a margin of safety below book value or at least near it before I show any interest. This is a possible turnaround situation, but the turn has not yet appeared in the numbers.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer